Search Results

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio) today announced the clinical data of the Company’s HBV ASO molecule, AHB-137, will be presented in two late-breaking posters, LBP-019 and LBP-043, at the annual European Association for the Study of the Liver (EASL™) Congress 2024, to be held in Milan, Italy, from June 5th to 8th, 2024.

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. announced significant updates on the clinical development of its leading molecule, AHB-137, an unconjugated antisense oligonucleotide targeting all HBV RNA.

AlzeCure Pharma AB announced that the company has selected a TrkA-NAM drug candidate, ACD137, and started the preclinical development phase with the compound.